SG11202002503TA - Biomarker - Google Patents

Biomarker

Info

Publication number
SG11202002503TA
SG11202002503TA SG11202002503TA SG11202002503TA SG11202002503TA SG 11202002503T A SG11202002503T A SG 11202002503TA SG 11202002503T A SG11202002503T A SG 11202002503TA SG 11202002503T A SG11202002503T A SG 11202002503TA SG 11202002503T A SG11202002503T A SG 11202002503TA
Authority
SG
Singapore
Prior art keywords
biomarker
Prior art date
Application number
SG11202002503TA
Other languages
English (en)
Inventor
Alexandre Akoulitchev
Aroul Ramadass
Ewan Hunter
Matthew Salter
Original Assignee
Oxford Biodynamics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biodynamics Ltd filed Critical Oxford Biodynamics Ltd
Publication of SG11202002503TA publication Critical patent/SG11202002503TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202002503TA 2017-10-02 2018-10-01 Biomarker SG11202002503TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566756P 2017-10-02 2017-10-02
PCT/GB2018/052808 WO2019069067A1 (en) 2017-10-02 2018-10-01 BIOMARKER

Publications (1)

Publication Number Publication Date
SG11202002503TA true SG11202002503TA (en) 2020-04-29

Family

ID=63834322

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002503TA SG11202002503TA (en) 2017-10-02 2018-10-01 Biomarker

Country Status (11)

Country Link
US (1) US12006547B2 (https=)
EP (1) EP3692168A1 (https=)
JP (2) JP2020537514A (https=)
KR (1) KR102762920B1 (https=)
CN (1) CN111344415B (https=)
AU (1) AU2018344573B2 (https=)
CA (1) CA3076450A1 (https=)
MY (1) MY200184A (https=)
SG (1) SG11202002503TA (https=)
WO (1) WO2019069067A1 (https=)
ZA (1) ZA202001821B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI884984B (zh) * 2019-09-11 2025-06-01 英商牛津生物力學公眾有限公司 診斷染色體標記
GB202016176D0 (en) * 2020-10-12 2020-11-25 Oxford BioDynamics PLC Disease marker
JP2024504062A (ja) * 2021-01-07 2024-01-30 オックスフォード バイオダイナミックス ピーエルシー 染色体相互作用
CN117203350A (zh) * 2021-01-07 2023-12-08 牛津生物动力公共有限公司 染色体相互作用
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
AU2006264564B2 (en) * 2005-07-04 2012-04-19 Erasmus University Medical Center Chromosome conformation capture-on-chip (4c) assay
GB0810051D0 (en) 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
JP5503942B2 (ja) * 2009-10-30 2014-05-28 シスメックス株式会社 疾患の罹患の判定方法
US8663919B2 (en) * 2011-05-18 2014-03-04 Life Technologies Corporation Chromosome conformation analysis
JP2018527016A (ja) * 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出
WO2017001568A1 (en) 2015-07-01 2017-01-05 Universitat De Lleida Treatment and prevention of amyotrophic lateral sclerosis
WO2018115802A1 (en) 2016-12-23 2018-06-28 Oxford Biodynamics Limited Typing method

Also Published As

Publication number Publication date
ZA202001821B (en) 2022-10-26
MY200184A (en) 2023-12-12
JP2023182591A (ja) 2023-12-26
AU2018344573A1 (en) 2020-04-09
JP2020537514A (ja) 2020-12-24
CN111344415B (zh) 2024-04-30
CA3076450A1 (en) 2019-04-11
NZ762713A (en) 2025-03-28
KR102762920B1 (ko) 2025-02-04
WO2019069067A1 (en) 2019-04-11
EP3692168A1 (en) 2020-08-12
KR20200058527A (ko) 2020-05-27
JP7701419B2 (ja) 2025-07-01
US12006547B2 (en) 2024-06-11
AU2018344573B2 (en) 2020-09-17
CN111344415A (zh) 2020-06-26
US20200407790A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
GB2566681B (en) Biomarker
GB201420908D0 (en) Biomarkers
GB201614455D0 (en) Biomarkers
GB201401603D0 (en) Biomarkers
SG10202007262PA (en) Copanlisib biomarkers
GB201703058D0 (en) Biomarkers
SG10202007322PA (en) Copanlisib biomarkers
ZA202001821B (en) Biomarker
GB201710858D0 (en) Biomarker
GB201704267D0 (en) Novel biomarker
GB201500729D0 (en) Novel Biomarkers
GB201804648D0 (en) Combination biomarker
GB201703123D0 (en) Biomarkers
GB201512133D0 (en) Biomarkers
GB201420239D0 (en) Biomarker
GB201416015D0 (en) Biomarker
GB201811093D0 (en) Biomarker
GB201704620D0 (en) Combinations
IL268770A (en) Aptamer as a biomarker
GB201603002D0 (en) Inflammation biomarker
GB201707113D0 (en) Biomarker
GB201720776D0 (en) Biomarkers
GB201706669D0 (en) Biomarkers
GB201807367D0 (en) Biomarker
GB201702986D0 (en) Biomarkers